Evidence to Support Monitoring of Vedolizumab Trough Concentrations in Patients With Inflammatory Bowel Diseases

Erwin Dreesen(KU Leuven), Séverine Vermeire(KU Leuven), Bram Verstockt(Universitair Ziekenhuis Leuven), Gert Van Assche(KU Leuven), Sumin Bian(Westlake University), Magali de Bruyn(KU Leuven), Ann Gils(KU Leuven), Griet Compernolle(KU Leuven), Maja Noman(KU Leuven), Sophie Tops(KU Leuven), Marc Ferrante(Universitair Ziekenhuis Leuven)
Clinical Gastroenterology and Hepatology
April 25, 2018
10.1016/j.cgh.2018.04.040
Cited by 158

Related Papers

Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k
A decrease of the butyrate-producing species <i>Roseburia hominis</i> and <i>Faecalibacterium prausnitzii</i> defines dysbiosis in patients with ulcerative colitis
|Gut|2013|1.9k
ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications
|Journal of Crohn s and Colitis|2018|1.8k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k